Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis
| العنوان: | Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis |
|---|---|
| المؤلفون: | Paolo Gisondi, Giampiero Girolomoni, Francesco Bellinato, Luca Idolazzi, Giovanni Targher |
| المصدر: | Annals of the Rheumatic Diseases. 81:68-73 |
| بيانات النشر: | BMJ, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, Time Factors, tumor necrosis factor inhibitors, Arthritis, Etanercept, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, Ultraviolet light, Immunology and Allergy, Cumulative incidence, psoriatic arthritis, Incidence, Incidence (epidemiology), Age Factors, Middle Aged, arthritis, Italy, biological therapy, Antirheumatic Agents, Female, Ultraviolet Therapy, Ustekinumab, medicine.medical_specialty, Immunology, Antibodies, Monoclonal, Humanized, Lower risk, General Biochemistry, Genetics and Molecular Biology, Nail Diseases, 03 medical and health sciences, Psoriatic arthritis, Rheumatology, Internal medicine, Psoriasis, medicine, Humans, Proportional Hazards Models, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, business.industry, Proportional hazards model, Arthritis, Psoriatic, Adalimumab, medicine.disease, Infliximab, Nails, business, Follow-Up Studies |
| الوصف: | ObjectiveTo estimate the incidence of psoriatic arthritis (PsA) in patients with psoriasis who had received a continuous treatment with biological disease-modifying antirheumatic drugs (bDMARDs) compared with phototherapy.MethodsA retrospective non-randomised study involving patients with moderate-to-severe plaque psoriasis, who were prescribed at least 5 years of bDMARDs or at least three narrow-band ultraviolet light B (nb-UVB) phototherapy courses, and did not have a diagnosis of PsA at enrolment. Development of PsA in each patient was assessed by a rheumatologist according to the Classification for Psoriatic Arthritis criteria. The annual and cumulative incidence rate of PsA was estimated by using an event per person-years analysis. Cox proportional hazards models were undertaken to assess the hazard risk (HR) of PsA after adjustment for confounders.ResultsA total of 464 psoriatic patients (bDMARDs, n=234 and nb-UVB, n=230) were followed between January 2012 and September 2020 (corresponding to 1584 and 1478 person year of follow-up for the two groups, respectively). The annual incidence rate of PsA was 1.20 cases (95% CI 0.77 to 1.89) versus 2.17 cases (95% CI 1.53 to 3.06) per 100 patients/year in the bDMARDs versus phototherapy group, respectively (HR 0.29, 0.12–0.70; p=0.006). The variables independently associated with higher risk of PsA were older age (adjusted HR 1.04, 1.02–1.07), nail psoriasis (adjusted HR 3.15, 1.63–6.06) and psoriasis duration >10 years (adjusted HR 2.02, 1.09–3.76); notably, bDMARDs treatment was associated with a lower risk of incident PsA (adjusted HR 0.27, 0.11–0.66).ConclusionsbDMARDs treatment may delay or reduce the risk of incident PsA in patients with moderate-to-severe chronic plaque psoriasis. |
| تدمد: | 1468-2060 0003-4967 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb3211a15160ce5f6af89e1acd1b395Test https://doi.org/10.1136/annrheumdis-2021-219961Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9fb3211a15160ce5f6af89e1acd1b395 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14682060 00034967 |
|---|